Abstract
HupA is a potent, reversible and selective inhibitor of AChE with a rapid absorption and penetration into the brain in animal tests. It exhibits memory-enhancing activities in animal and clinical trials. Compared to tacrine and donepezil, HupA possesses a longer duration of action and higher therapeutic index, and the peripheral cholinergic side effects are minimal at therapeutic doses. This review article deals with a comprehensive survey of the progress in chemical and pharmacological studies of HupA including the isolation and structure elucidation, pharmacological actions, total synthesis, SAR studies and the future development of HupA. Recently, it has been reported that HupA could reduce neuronal cell death caused by glutamate. The dual bio-activities of HupA would further enhance its value and potentiality as the therapeutic agent for Alzheimers disease.
Keywords: huperzine A, inhibitor of AChE, revesibile inhibitors if AChE, lycopoduim, HupA, Huperzia serrata, alzheimer s disease, glutamate, dual bio activities, neuronal cell death, structure elucidation, pharmacological actions, total synthesis, SAR studies, donepezil, brain receptor, learning, memory, cyvlohexanedione mono ethylene ketal 10, keto ester, pyridine derivatives, dimethyl 4 oxopimelate, recemic HupA, stereiselective michael aldok reaction, diastereomeric separation, chiral catalyst, natura HupA, enantioselective palladium catalyzed bicycloannulation, structure activity relationships, the anti AChE activities, zusammen together, entgegen, lithium aluminium hydride, enantiomer excess, tetramethylguanidine, rectus, sinister left
Current Medicinal Chemistry
Title: Huperzine A, A Potential Therapeutic Agent for Treatment of Alzheimers Disease
Volume: 7 Issue: 3
Author(s): D. L. Bai, X. C. Tang and X. C. He
Affiliation:
Keywords: huperzine A, inhibitor of AChE, revesibile inhibitors if AChE, lycopoduim, HupA, Huperzia serrata, alzheimer s disease, glutamate, dual bio activities, neuronal cell death, structure elucidation, pharmacological actions, total synthesis, SAR studies, donepezil, brain receptor, learning, memory, cyvlohexanedione mono ethylene ketal 10, keto ester, pyridine derivatives, dimethyl 4 oxopimelate, recemic HupA, stereiselective michael aldok reaction, diastereomeric separation, chiral catalyst, natura HupA, enantioselective palladium catalyzed bicycloannulation, structure activity relationships, the anti AChE activities, zusammen together, entgegen, lithium aluminium hydride, enantiomer excess, tetramethylguanidine, rectus, sinister left
Abstract: HupA is a potent, reversible and selective inhibitor of AChE with a rapid absorption and penetration into the brain in animal tests. It exhibits memory-enhancing activities in animal and clinical trials. Compared to tacrine and donepezil, HupA possesses a longer duration of action and higher therapeutic index, and the peripheral cholinergic side effects are minimal at therapeutic doses. This review article deals with a comprehensive survey of the progress in chemical and pharmacological studies of HupA including the isolation and structure elucidation, pharmacological actions, total synthesis, SAR studies and the future development of HupA. Recently, it has been reported that HupA could reduce neuronal cell death caused by glutamate. The dual bio-activities of HupA would further enhance its value and potentiality as the therapeutic agent for Alzheimers disease.
Export Options
About this article
Cite this article as:
Bai L. D., Tang C. X. and He C. X., Huperzine A, A Potential Therapeutic Agent for Treatment of Alzheimers Disease, Current Medicinal Chemistry 2000; 7 (3) . https://dx.doi.org/10.2174/0929867003375281
DOI https://dx.doi.org/10.2174/0929867003375281 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evaluation of Pectin as a Material for Hepatocyte Encapsulation
Micro and Nanosystems Nanostructured Lipid Carriers for Intranasal Administration of Olanzapine in the Management of Schizophrenia
Current Molecular Pharmacology Purine Molecules as Hypnogenic Factors Role of Adenosine, ATP, and Caffeine
Central Nervous System Agents in Medicinal Chemistry Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Plant Plastid Engineering
Current Genomics Treatment Options in Alzheimer´s Disease: The GABA Story
Current Pharmaceutical Design Electroacupuncture Reduces Hemiplegia Following Acute Middle Cerebral Artery Infarction with Alteration of Serum NSE, S-100B and Endothelin
Current Neurovascular Research Psychiatric Manifestations of Ehlers-Danlos Syndrome in Adolescents: A Case Report and Literature Review
Current Psychiatry Research and Reviews Treating Benign Prostatic Hyperplasia with Botulinum Neurotoxin
Current Medicinal Chemistry DNA Methylation Markers in Lung Cancer
Current Genomics Effects of Resveratrol and other Polyphenols on Sirt1: Relevance to Brain Function During Aging
Current Neuropharmacology Human 5-HT4 and 5-HT7 Receptor Splice Variants: Are they Important?
Current Neuropharmacology Cdk5 in the Adult Non-Demented Brain
Current Drug Targets - CNS & Neurological Disorders Interactions of VIP, Secretin and PACAP1-38 with Phospholipids: A Biological Paradox Revisited
Current Pharmaceutical Design The Role of ER Stress-Induced Apoptosis in Neurodegeneration
Current Alzheimer Research Current Drug Targets and Future Therapy of Pulmonary Arterial Hypertension
Current Medicinal Chemistry Drugs of Abuse and their Detection Methodologies: Contribution of Chemical Sensor
Current Organic Chemistry Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment
Current Topics in Medicinal Chemistry Long-Term Outcome of Cardio Respiratory Exercise Performance After Surgery
Current Respiratory Medicine Reviews Editorial from Guest Editor (DNA Methylation: A Target for Current and Future Therapies?)
Epigenetic Diagnosis & Therapy (Discontinued)